Sort
15,273 grants matching “antimicrobial resistance”
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** THE EXTENSIVE USE OF ANTIBIOTICS IN LIVESTOCK FARMING POSES A SIGNIFICANT PUBLIC HEALTH RISK WITH WIDESPREAD CONSEQUENCES. ANIMAL AGRICULTURE GENERATES CONSIDERABLE WASTE, FOSTERING THE RAPID GROWTH AND SPREAD OF DISEASE-CAUSING PATHOGENS IN THE ENVIRONMENT. TO COMBAT THIS, FARMERS OFTEN RESORT TO USING MEDICALLY IMPORTANT ANTIBIOTICS TO CONTROL THE SPREAD OF DISEASES AMONG THEIR LIVESTOCK. HOWEVER, THIS PRACTICE EXPOSES BOTH HARMLESS AND HARMFUL BACTERIA TO ANTIBIOTICS, LEADING TO THE EMERGENCE AND DISSEMINATION OF ANTIMICROBIAL RESISTANCE (AMR). CONSEQUENTLY, THE FARMING ENVIRONMENT BECOMES A BREEDING GROUND FOR ANTIBIOTIC-RESISTANT BACTERIA, WHICH CAN THEN INFECT HUMANS EITHER THROUGH DIRECT CONTACT OR THE FOOD CHAIN. RECOGNIZING THAT FOOD ANIMALS NOT ONLY TRANSMIT BUT ALSO CONTRIBUTE TO THE PROLIFERATION OF ANTIBIOTIC-RESISTANT BACTERIA, MANY COUNTRIES HAVE IMPLEMENTED STRICTER REGULATIONS ON ANTIBIOTIC USE IN LIVESTOCK FARMING. THESE REGULATIONS TYPICALLY RESTRICT ANTIBIOTIC USAGE AND MANDATE VETERINARY SUPERVISION. THE US GOVERNMENT, FOR INSTANCE, HAS IMPOSED LIMITATIONS ON ANTIBIOTIC USAGE IN ANIMAL FARMING TO COMBAT THE OVERUSE AND MISUSE OF THESE DRUGS, WHICH CAN SPAWN ANTIBIOTIC-RESISTANT STRAINS. HOWEVER, IT'S CRUCIAL TO ACKNOWLEDGE THE CHALLENGES FACED BY HISTORICALLY UNDERSERVED FARMERS IN COMPLYING WITH THESE REGULATIONS. SUCH FARMERS OFTEN ENCOUNTER UNIQUE OBSTACLES SUCH AS DISEASE MANAGEMENT, WATER CONTAMINATION, LIMITED ACCESS TO VETERINARY SERVICES, AND INADEQUATE RESOURCES AND EDUCATION ON BEST PRACTICES, ALL OF WHICH CAN IMPACT THE PREVALENCE OF POULTRY DISEASES AND THE SPREAD OF AMR.THE OVERARCHING GOALOF THIS PROJECTIS TO ESTABLISH AN EDUCATIONAL AND TRAINING PROGRAM ON ANTIMICROBIAL STEWARDSHIP, SPECIFICALLY TAILORED TO EMPOWER HISTORICALLY UNDERSERVED POULTRY PRODUCERS. BY IMPARTING KNOWLEDGE AND FOSTERING PRACTICES SUCH AS GOOD FARMING TECHNIQUES, BIOSECURITY MEASURES, AND THE ESTABLISHMENT OF STRONG VETERINARIAN-CLIENT-PATIENT RELATIONSHIPS, THIS WILLREDUCE THE INCIDENCE AND SPREAD OF POULTRY DISEASES WHILE MINIMIZING ANTIMICROBIAL USAGE ON POULTRY FARMS. ADDITIONALLY, THE PROJECT SEEKS TO INTRODUCE INNOVATIVE SOLUTIONS SUCH AS UV LIGHT COMBINED WITH PERACETIC ACID TO COMBAT MICROBIAL CONTAMINATION AND BIOFILM FORMATION IN KEY AREAS SUCH AS WATER SYSTEMS. UV-C IRRADIATION WILL ALSO BE UTILIZED TO CONTROL MICROBIAL CONTAMINATION ON EGG SURFACES. THE PROJECT ALSO AIMS TO ENHANCE THE CAPABILITIES OF EXTENSION EDUCATORS AND PRODUCERS IN POULTRY DISEASES AND ANTIMICROBIAL RESISTANCE THROUGH WORKSHOPS.WELL-TRAINED EXTENSION PERSONNEL WILL SERVE AS CONDUITS FOR TRANSFERRING KNOWLEDGE TO PRODUCERS AND EFFECTIVELY ENGAGING WITH THEIR CLIENTELE. BY SIMPLIFYING COMPLEX TOPICS RELATED TO POULTRY DISEASES AND ANTIMICROBIAL RESISTANCE, THEY WILL EMPOWER HISTORICALLY UNDERSERVED POULTRY PRODUCERS WITH VALUABLE INSIGHTS AND INFORMATION.
$486,310Tennessee State University · · FY2024 · National Institute of Food and Agriculture
Dual-Stimuli Responsive Antibiotic-Loaded Nanoparticles: A New Strategy to Overcome Antimicrobial Resistance
$486,236Shaoqin - Gong · University Of Wisconsin-Madison · R01 · FY2024 · AI
Digital High Resolution Melt and Machine Learning for Rapid and Specific Diagnosis in Neonatal Sepsis
$486,161Stephanie Irene Fraley · University Of California, San Diego · R01 · FY2020 · AI
Nanoparticle Modified Textiles for Protective Clothing
$485,844Waheguru P Singh · Lynntech, Inc. · R44 · FY2008 · AI
Aneuploidy and Acquired Antifungal Drug Resistance in Candida species
$485,674Anna M. Selmecki · University Of Minnesota · R01 · FY2025 · AI
NeoChip for specific and rapid identification of congenital CMV and neonatal HSV infections on minimal sample volume
$485,605Shelley M Lawrence · University Of Utah · R01 · FY2024 · HD
VACCINE TREATMENT AND EVALUATION UNIT: PHASE I/II THERAPEUTIC TRIAL FOR CLOSTRIDIUM DIFFICILE
$485,489Clarence Buddy Creech · · N01 · FY2017 · AI
A Novel Antimicrobial Mimetic for Oral Candidiasis
$485,458Richard W Scott · Polymedix, Inc, · R44 · FY2010 · DE
Multi-Drug Resistant Urinary Tract Infections in Ambulatory Settings
$485,349Ebbing Lautenbach · University Of Pennsylvania · R18 · FY2011 · HS
Tolerance defenses in host-microbiota interactions
$485,000Janelle S Ayres · Salk Institute For Biological Studies · R01 · FY2016 · AI
Tolerance defenses in host-microbiota interactions
$485,000Janelle S Ayres · Salk Institute For Biological Studies · R01 · FY2017 · AI
Tolerance defenses in host-microbiota interactions
$485,000Janelle S Ayres · Salk Institute For Biological Studies · R01 · FY2019 · AI
Tolerance defenses in host-microbiota interactions
$485,000Janelle S Ayres · Salk Institute For Biological Studies · R01 · FY2015 · AI
OUR HYPOTHESIS IS THAT CHRONIC BOVINE RESPIRATORY DISEASE (BRD) IS A BACTERIAL BIOFILM DISEASE, WHICH MAKES THE BACTERIAL PATHOGENS ASSOCIATED WITH BRD MORE RESISTANT TO ANTIBIOTICS AND HOST IMMUNE DEFENSES. A BIOFILM IS AN ORGANIZED STRUCTURE OF BACTERIAL CELLS THAT ARE ENCASED IN A NETWORK OF POLYSACCHARIDE, NUCLEIC ACIDS, AND PROTEINS. THIS MATRIX MATERIAL CONTAINS WATER CHANNELS TO PROVIDE NUTRIENTS TO CELLS DEEP WITHIN THE BIOFILM, BUT THE CELLS THEMSELVES, THOUGH VIABLE, GROW VERY SLOWLY. AS A RESULT, BACTERIA WITHIN A BIOFILM ARE MORE RESISTANT TO ANTIBIOTICS AND HOST IMMUNE FACTORS DUE TO INACCESSIBILITY AND THE SLOW GROWTH OF THE BACTERIA (ANTIBIOTICS USUALLY ONLY KILL ACTIVLY GROWING CELLS). THE PRIMARY BACTERIAL PATHOGENS ASSOCIATED WITH BRD ARE HISTOPHILUS SOMNI, PASTEURELLA MULTOCIDA, MANNHEIMIA HAEMOLYTICA, AND MYCOPLASMA SPP., AND THEY MAY OCCUR ALONE, IN COMBINATION WITH EACH OTHER, OR WITH VIRAL AGENTS. THIS PROJECT FOCUSES ON THE RELATED BACTERIA H. SOMNI, P. MULTOCIDA, AND M. HAEMOLYTICA. THESE ORGANISMS RESIDE ONLY IN HOST MUCOSAL SITES, AND H. SOMNI AND M. HAEMOLYTICA RESIDE ONLY IN RUMINANTS (PRIMARILY BOVINES AND SHEEP). WE AND OTHERS HAVE ESTABLISHED THAT EACH OF THESE OPPORTUNISTIC PATHOGENS ARE CAPABLE OF FORMING BIOFILMS ON COVER SLIPS, TUBES, CULTURE PLATE WELLS, AND IN THEIR NATURAL HOST. WE HAVE ALSO SHOWN THAT H. SOMNI AND P. MULTOCIDA FORM A POLY-MICROBIAL BIOFILM TOGETHER IN LABORATORY VESSELS AND IN HOST TISSUES. HOWEVER, IT IS ESSENTIAL TO UNDERSTAND IF ALL 3 BACTERIA INTERACT TO FORM A BIOFILM TOGETHER, AND HOW SINGLE- AND POLY-MICROBIAL BIOFILMS DEVELOP AND BECOME ESTABLISHED IN THE HOST. ALTHOUGH CURRENT VACCINES DO INDUCE ANTIBODIES TO THESE BACTERIA, THAT ARE NOT ADEQUATELY EFFECTIVE AGAINST BRD. ANTIMICROBIALS ARE EXPENSIVE, AND EVEN IF EFFECTIVE, REQUIRE LONG PERIODS OF TREATMENT. WE PROPOSE THAT THE INEFFECTIVENESS OF CURRENT VACCINES AND ANTIMICROBIALS IS BECAUSE THE BACTERIA HAVE BECOME ESTABLISHED IN A BIOFILM, BUT THERE IS A LACK OF UNDERSTANDING OF HOW THESE BIOFILMS DEVELOP IN HOST TISSUES, AND HOW TO ELIMINATE OR REDUCE THE BIOFILM. THIS PROPOSAL AIMS TO FILL SOME OF THOSE GAPS IN KNOWLEDGE, AND IDENTIFY COMPOUNDS THAT MAY ENHANCE THE EFFICACY OF VACCINES AND ANTIMICROBIAL AGENTS.WE WILL FIRST DETERMINE IF ALL 3 OF THE BACTERIAL PATHOGENS MENTIONED ABOVE FORM A POLY-MICROBIAL BIOFILM TOGETHER (OUR FIRST AIM), AND THEN HOW THIS BIOFILM BECOMES ESTABLISHED AND DEVELOPS IN THE HOST THROUGH THE USE OF 3-D TISSUE CULTURE USING BOVINE RESPIRATORY EPITHELIAL CELLS (OUR SECOND AIM). THIS TYPE OF CELL CULTURE CAN MOST CLOSELY APPROXIMATE WHAT OCCURS IN THE BOVINE USING A MODEL THAT CAN BE OBSERVED ON AN HOURLY OR DAILY BASIS. WE WILL ALSO SCREEN AN EXTENSIVE LIBRARY OF THOUSANDS OF COMPOUNDS FOR THEIR CAPABILITY TO BREAK UP A SINGLE OR POLY-MICROBIAL BIOFILM, AND THOSE COMPOUNDSTHAT ARE DETERMINED TO BE SAFE FOR USE IN ANIMALS WILL BE FURTHER TESTED TO BREAK UP THE BIOFILM IN THE 3-D TISSUE CULTURE MODEL.,THEREAFTER, USING AN ANTIMICROBIAL BIOFILM DEVICE ASSAY, WE WILL DETERMINE IF THE BACTERIA WITHIN A BIOFILM ARE SIGNIFICANTLY MORE SUSCEPTIBLE TO A COMBINATION OF THE ANTIMICROBIAL AND THE ANTI-BIOFILM COMPOUND, THAN THE ANTIMICROBIAL ALONE (OUR THIRD AIM). IF SO, FURTHER DEVELOPMENT OF THESE COMPOUNDS WILL BE EXPLORED WITH PHARMACEUTICAL COMPANIES.IF SUCCESSFUL, THIS WORK WILL HAVE BENEFITS TO SOCIETY THATEXTEND MUCH FARTHER THAN ONLY TO IMPROVED TREATMENT OF BRD. BIOFILMS ARE COMMON IN MANY BACTERIAL DISEASES OF ANIMALS AND HUMANS, INCLUDING SWINE ATROPHIC RHINITIS, HUMAN CYSTIC FIBROSIS, ENDOCARDITIS, OSTEOMYELITIS, AND OTHERS. WE HOPE THAT THIS WORK WILL LEAD TO TREATMENT AND REMOVAL OF THE BIOFILM TO OBTAIN IMPROVED RESOLUTION OF CHRONIC BACTERIAL INFECTIONS.
$485,000Long Island University · · FY2019 · National Institute of Food and Agriculture
A Trial to Explore the Benefits of Antimicrobial Self-Sanitizing Surfaces on Bio-Burden Levels and Healthcare-Acquired Infections.
$484,985Chetan Jinadatha · Central Texas Veterans Research Foundation · R01 · FY2019 · HS
Microbiome in TB treatment response and disease resolution
$484,835Sabine Ehrt · Weill Medical Coll Of Cornell Univ · U19 · FY2023 · AI
Implementation and Evaluation of a Video-based Prospective Feedback Intervention to Improve Antimicrobial Stewardship in Neonatal Intensive Care Units
$484,815Peter James Mendel · Rand Corporation · R18 · FY2020 · HS
The Contribution of Ribonuclease 7 to Urinary Tract Anitbacterial Defense
$484,792John David Spencer · Research Inst Nationwide Children'S Hosp · R01 · FY2022 · DK
The Contribution of Ribonuclease 7 to Urinary Tract Anitbacterial Defense
$484,792John David Spencer · Research Inst Nationwide Children'S Hosp · R01 · FY2021 · DK
Type 1 diabetes: the role of commensal microbiota
$484,709Alexander V Chervonsky · University Of Chicago · R01 · FY2017 · AI
Type 1 diabetes: the role of commensal microbiota
$484,709Alexander V Chervonsky · University Of Chicago · R01 · FY2019 · AI
Type 1 diabetes: the role of commensal microbiota
$484,709Alexander V Chervonsky · University Of Chicago · R01 · FY2020 · AI
Synovial Fluid and Joint Sepsis
$484,576Noreen J Hickok · Thomas Jefferson University · R01 · FY2020 · AR
Development of antibacterial agents and materials
$484,437Joel Schneider · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Susceptibility and resistance of multidrug-resistant gram-negative bacteria to novel beta-lactam/beta-lactamase inhibitor combinations
$484,436Thea Brennan-Krohn · Beth Israel Deaconess Medical Center · R01 · FY2023 · AI